CAAP Company: ScarX Therapeutics closes $2 million Series A financing
Feb. 16, 2016 Toronto - ScarX Therapeutics, a Canadian biotechnology company commercializing innovative treatments for dermal scarring (fibrosis), has closed a $2 million Series A financing. The company will complete a Phase I clinical trial of its lead candidate, SCX-001, in human volunteers, with the eventual goal of creating better functional and cosmetic patient outcomes.
OBIO applauds federal funding for Natural Products Canada
February 12, 2016 – Toronto Ontario. Today, the Ontario Bioscience Innovation Organization welcomes the creation of Natural Products Canada Inc. (NPC), the nation’s newest Centre of Excellence for Commercialization and Research. Press Release. Click here for the press release.
Self Care Cataysts - Featured Article, Inc. Magazine
Grace Soyao, Founder & CEO, Self Care Catalysts Inc. writes about "Creating Breakthroughs in Entreprneurship" in 4 key steps.
Click here for the full article
Interface Biologics Announces the Extension of its Licensing Agreement with Fresenius Medical Care
TORONTO, Canada, February 9, 2016 - Interface Biologics Inc. (IBI) is pleased to announce that Fresenius Medical Care, the worlds’ largest integrated provider of dialysis products and services, has extended their exclusive licensing agreement for use of Endexo™ technology in chronic dialysis systems to cover the acute dialysis market (including CRRT).
Focal Healthcare receives 510(k) clearance from the FDA for their targeted prostate biopsy device, Fusion Bx
Toronto, ON – January 29, 2016 – Focal Healthcare Inc.TM, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for their targeted prostate biopsy device, Fusion Bx TM.
PlantForm Corporation awarded Government of Canada contract for plant-based production of anti-ricin antibody
lantForm Corporation has received a Government of Canada contract for the plant-based production of an antibody being studied by Defence Research and Development Canada (DRDC) as an antidote to ricin exposure.
Sernova Honoured as Member of the “2016 TSX Venture 50” and Ranked #4 in Life Sciences and Clean Technologies
Sernova Honoured as Member of the “2016 TSX Venture 50” and Ranked #4 in Life Sciences and Clean Technologies. Sernova resides in the top 3% of TSX Venture Exchange Companies in market performance.
TO Health! announces its evolution and Summit to make Toronto region cluster Top 5 in 10
TORONTO, Feb. 2, 2016 - TO Health! today announced its evolution and strategy to raise the profile of the Toronto Region Human Health and Sciences (HHS) cluster. The vision of the initiative is to make the Toronto region a Top 5 global health science cluster in the next 10 years.
Rna Diagnostics announces new study in chemotherapy efficacy in canine lymphoma
Rna Diagnostics Inc announced today a new study to investigate RDA as a predictor for chemotherapy efficacy in canine lymphoma in partnership with University of Guelph Institute for Comparative Cancer Investigation and the Mona Campbell Centre for Animal Cancer at the Ontario Veterinary College. This study of canine lymphoma is based on the success of an initial canine lymphoma study completed in 2014.
CAAP Company: Conavi Medical (formerly Colibri Technologies) announces FDA 510k clearance for its first product, the Foresight ICE System for Intracardiac Echocardiography
TORONTO, Jan. 14, 2016 /PRNewswire/ - Conavi Medical Inc. (formerly Colibri Technologies Inc.) has received United States (US) Food and Drug Administration (FDA) 510(k) clearance for the Foresight ICE System for intracardiac and intraluminal ultrasound visualization of cardiac and great vessel anatomy as well as visualization of other devices in the heart and great vessels of patients
NOVADAQ Announces Fourth Quarter 2015 Preliminary Unaudited Revenues and Issues 2016 Revenue Guidance
TORONTO, Jan. 11, 2016 (GLOBE NEWSWIRE) -- Novadaq Technologies Inc. (“NOVADAQ” or the “Company”) (NVDQ) (NDQ.TO), the leading developer and provider of clinically relevant fluorescence imaging solutions for use in surgical and diagnostic procedures, announced today preliminary unaudited revenue for the fourth quarter of 2015 and provided 2016 revenue guidance ahead of its participation at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco, CA.
Moseda Announces Appointment of Experienced Healthcare Technology Executive
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jan. 18, 2016) - Moseda Technologies Inc. (TSX VENTURE:MSD) ("Moseda" or the "Company"), a technology company focused on developing progressive mobile health (mHealth) and telemedicine solutions for institutional and home healthcare, is pleased to announce that it has appointed industry expert Dr. Lisa Crossley, PhD., P.Eng. as CEO and Director and Mr. Sameet Kanade as President and Chairman of the Board as the Company aims to ramp up its client acquisition strategy.
OBIO Announces Pre-Capital Access Advisory Program for 2016
Toronto, Ontario, January 19, 2016 – Ontario Bioscience Innovation Organization (OBIO®) today announced the 2016 Pre-Capital Access Advisory Program (Pre-CAAP), a program in support of Ontario’s early stage bioscience companies. With access to capital as the number one challenge for bioscience start-ups in Ontario, Pre-CAAP combined with OBIO’s distinctive Capital Access Advisory Program (CAAP®) provides companies with key knowledge and insights to position them for financing and commercial success.
Proteocyte Receives Support from NRC-IRAP for Straticyte™ Intellectual Property Development
Proteocyte Diagnostics Inc. today announced the completion of a project enhancing the current version of Straticyte™ and opening up new potential applications. This significant advancement has led to additional Intellectual Property and value creation for the Company.
Vive Crop Protection Receives EPA Registration for Bifender At-Plant Insecticide
The United States Environmental Protection Agency has approved Vive Crop Protection's Bifender™ insecticide using Vive's proprietary Allosperse® delivery technology. The product contains bifenthrin, an excellent broad-spectrum insecticide, and is targeted for early-season in-furrow or soil applications.
CAAP Company: Induce Biologics Signs Exclusive License & Distribution Agreement with Antibe Therapeutics
January 12, 2016, Toronto — Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQX: ATBPF), a commercial-stage healthcare company focused on pain, inflammation and regenerative medicine, is pleased to announce the signing of an exclusive Licensing and Distribution Agreement with Induce Biologics Inc. (“Induce”) for the Canadian rights for Induce’s URIST(TM) biological product for dental and craniofacial applications.
For the full press release click here
Sernova Corp to Present at the Biotech Showcase(TM) 2016 in San Francisco on January 13, 2016
Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH), a clinical stage regenerative medicine company, today announced that Dr. Philip Toleikis, Sernova’s President and CEO, will be providing a corporate update at the 8th annual Biotech Showcase Conference in San Francisco, CA, at 4:00 p.m. PST on January 13, 2016 in San Francisco, California.
In a full roster of business development meetings, Dr. Toleikis will also be updating key pharma and institutional audiences on the company's progress and future plans.
Gail Garland, OBIO CEO talks with BNN about Canada's health science industry
Gail Garland, OBIO CEO talks with BNN about the economic and health benefits that accrue to Canada by building a globally competitive Canadian health science industry. Click here for the full interview.
Proteocyte Receives Support from NRC-IRAP for Straticyte™
Proteocyte Diagnostics Inc. today announced the completion of a project enhancing the current version of Straticyte™ and opening up new potential applications.
SERNOVA AWARDED EUROPE’S PRESTIGIOUS HORIZON 2020 GRANT
Distinguished European consortium awarded approximately $8.5 Million CAD by the European Commission via its Horizon 2020 Program to partner advanced cell based Factor VIII therapy in collaboration with Sernova and its Cell Pouch(TM) device technologies.